FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. Pete O'Heeron, Founder and CEO, will represent the company.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents. Their presentation will be available on-demand to registered attendees starting September 9, 2024, at 7 a.m. Eastern Time.
Interested parties can find more information on FibroBiologics' website or by contacting info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG), una società biotech in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024, presso il Lotte New York Palace Hotel. Pete O'Heeron, Fondatore e CEO, rappresenterà la società.
FibroBiologics è specializzata nello sviluppo di terapie e potenziali cure per malattie croniche utilizzando fibroblasti e materiali derivati dai fibroblasti. La società vanta oltre 160 brevetti rilasciati e in attesa. La loro presentazione sarà disponibile su richiesta per i partecipanti registrati a partire dal 9 settembre 2024, alle 7:00, ora orientale.
Le parti interessate possono trovare ulteriori informazioni sul sito web di FibroBiologics o contattando info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG), una empresa biotecnológica en etapa clínica, anunció su participación en la 26ª Conferencia Global Anual de Inversiones de H.C. Wainwright. El evento está programado para el 9 al 11 de septiembre de 2024, en el Lotte New York Palace Hotel. Pete O'Heeron, Fundador y CEO, representará a la empresa.
FibroBiologics se especializa en el desarrollo de terapias y posibles curas para enfermedades crónicas utilizando fibroblastos y materiales derivados de fibroblastos. La empresa cuenta con más de 160 patentes otorgadas y pendientes. Su presentación estará disponible bajo demanda para los asistentes registrados a partir del 9 de septiembre de 2024, a las 7 a.m. hora del Este.
Las partes interesadas pueden encontrar más información en el sitio web de FibroBiologics o contactando a info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG), 임상 단계의 생명공학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 롯데 뉴욕 팰리스 호텔에서 개최될 예정입니다. Pete O'Heeron, 창립자 겸 CEO가 회사를 대표합니다.
FibroBiologics는 섬유아세포 및 섬유아세포 유래 물질을 사용하여 만성 질환에 대한 치료제와 잠재적인 치료법을 개발하는 데 전문성을 가지고 있습니다. 이 회사는 160개 이상의 특허가 발부되었거나 출원 중입니다. 그들의 발표는 2024년 9월 9일 오전 7시(동부 표준시)부터 등록된 참석자들에게 주문형으로 제공될 예정입니다.
관심 있는 당사자는 FibroBiologics 웹사이트에서 더 많은 정보를 찾거나 info@fibrobiologics.com으로 연락할 수 있습니다.
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement se tiendra du 9 au 11 septembre 2024 à l'Hôtel Lotte New York Palace. Pete O'Heeron, Fondateur et PDG, représentera l'entreprise.
FibroBiologics se spécialise dans le développement de thérapies et de traitements potentiels pour les maladies chroniques en utilisant des fibroblastes et des matériaux dérivés de fibroblastes. L'entreprise possède plus de 160 brevets délivrés et en attente. Leur présentation sera disponible à la demande des participants enregistrés à partir du 9 septembre 2024, à 7 h, heure de l'Est.
Les parties intéressées peuvent trouver plus d'informations sur le site web de FibroBiologics ou en contactant info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase, gab seine Teilnahme an der 26. Jahreskonferenz für globale Investitionen von H.C. Wainwright bekannt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel statt. Pete O'Heeron, Gründer und CEO, wird das Unternehmen vertreten.
FibroBiologics hat sich auf die Entwicklung von Therapien und möglichen Heilmethoden für chronische Krankheiten spezialisiert, wobei Fibroblasten und aus Fibroblasten gewonnene Materialien zum Einsatz kommen. Das Unternehmen kann über 160 erteilte und anhängige Patente vorweisen. Ihre Präsentation wird ab dem 9. September 2024, um 7 Uhr Eastern Time, für registrierte Teilnehmer auf Abruf verfügbar sein.
Interessierte Parteien können weitere Informationen auf der Website von FibroBiologics oder unter info@fibrobiologics.com anfordern.
- None.
- None.
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11 at the Lotte New York Palace Hotel in New York City.
FibroBiologics’ presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024, at 7 a.m. Eastern Time.
For more information, please visit FibroBiologics' website or email FibroBiologics at info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When and where is FibroBiologics (FBLG) presenting at the H.C. Wainwright conference?
What time will FibroBiologics' (FBLG) presentation be available on-demand?
What is the main focus of FibroBiologics' (FBLG) research?
How many patents does FibroBiologics (FBLG) have?
